BCM
MRSN

Bayesian Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Bayesian Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-504
Closed -$18K – 835
2024
Q4 		$18K Buy
+504
New +$26.1K ﹤0.01% 646
2024
Q1 		– Sell
-476
Closed -$27.6K – 994
2023
Q4 		$27.6K Buy
+476
New +$19.1K ﹤0.01% 691
2023
Q2 		– Sell
-992
Closed -$102K – 969
2023
Q1 		$102K Buy
+992
New +$139K 0.01% 684

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bayesian Capital Management's MRSN Position: Q1 2025 in Review

Bayesian Capital Management sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 504 shares — an estimated $18K sold.

Bayesian Capital Management first reported a position in MRSN in Q1 2023 and held it in 3 quarters. The position peaked at $102K in Q1 2023. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Bayesian Capital Management reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 504 Mersana Therapeutics shares in Q1 2025, an estimated $18K.
  • Bayesian Capital Management first reported a position in Mersana Therapeutics in Q1 2023 and held it in 3 quarters.
  • Bayesian Capital Management's Mersana Therapeutics position peaked at $102K in Q1 2023.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.